New York, New York-- (Newsfile Corp. - March 3, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and ...
2d
Fintel on MSNWilliam Blair Initiates Coverage of BioAge Labs (BIOA) with Market Perform RecommendationFintel reports that on February 28, 2025, William Blair initiated coverage of BioAge Labs (NasdaqGS:BIOA) with a Market ...
BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO– Hagens Berman
SAN FRANCISCO, Feb. 28, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) is abandoning development of its lead obesity candidate, azelaprag, just weeks after halting a Phase 2 trial.
On or about September 2024, BioAge conducted its IPO, selling 12.65 million shares of stock for $18 per share. On December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES ...
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of the March 10, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf ...
Class Action, Consumer Services, GlobeNewswire, Law & Legal Issues | NEW YORK, March 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law ...
RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against BioAge Labs, Inc.
NEW YORK CITY, NY / ACCESS Newswire / February 19, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ ...
LOS ANGELES, CA / ACCESS Newswire / February 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against BioAge Labs ...
SAN FRANCISCO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (NASDAQ: BIOA), a biopharmaceutical company focused on metabolic diseases, is facing a class-action lawsuit from shareholders who ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results